Michael J. Borrie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael J. Borrie has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Jennie L. Wells
Geriatric Rehabilitation Unit, Parkwood Hospital, London, ON, Canada
5 shared publications - Manuel Montero-Odasso
Division of Geriatric Medicine, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
4 shared publications - Corinne Eleanor Fischer
Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON M5B 1T8, Canada
3 shared publications - David F. Tang-Wai
University of Toronto, Temerty Faculty of Medicine, Department of Medicine, Division of Neurology, Toronto ON, Canada
3 shared publications - Maria Carmela Tartaglia
University Health Network
3 shared publications - Sanjeev Kumar
Centre for Addiction and Mental Health
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 29 (2) , 102-106
Geriatrician and General Internist Clinical Payments in Canada 2022–2023: Fee for Service and Alternative Payment Plan
A Comprehensive Geriatric Assessment (CGA) completed by a geriatrician assessing an older person living with frailty and multiple comorbidities involves longer visit durations than standard General Internal Medicine (GIM) consultations, reflecting the need for detailed evaluation. Medical trainees have little formal education about how they will be remunerated as specialists or that there are different methods of clinical payments between provinces of Canada, including Fee for Service (FFS) and Alternative Payment Plans (APP). GIM is a reasonable comparator to Geriatric Medicine because, while not using CGA, GIM residents are also trained to assess medically complex patients who often have comorbidities. The goal of this paper was to provide transparency for medical trainees about differences in the proportion of FFS or APP and the average clinical payments made to geriatricians and general internists between the provinces of Canada. Using data from the Canadian Institute for Health Information (CIHI), we show mean, mean trimmed to $100,000 and median clinical payments to geriatricians across Canada. Average payments were generally lower in provinces with predominantly an APP as the main source of payments compared to provinces with a split model of APP and FFS where payments demonstrated larger variances. The clinical payments to general internists were higher than for geriatricians. In addition to increasing transparency in specialist payments, Provincial Medical Associations and Sections or Divisions of Geriatric Medicine, could use these data to advocate for comparable remuneration between geriatricians and general internists when renegotiating clinical payments funding agreements.
- 3 June 2026
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 29 (2) , 102-106
Open AccessGeriatrician and General Internist Clinical Payments in Canada 2022–2023: Fee for Service and Alternative Payment Plan
A Comprehensive Geriatric Assessment (CGA) completed by a geriatrician assessing an older person living with frailty and multiple comorbidities involves longer visit durations than standard General Internal Medicine (GIM) consultations, reflecting the need for detailed evaluation. Medical trainees have little formal education about how they will be remunerated as specialists or that there are different methods of clinical payments between provinces of Canada, including Fee for Service (FFS) and Alternative Payment Plans (APP). GIM is a reasonable comparator to Geriatric Medicine because, while not using CGA, GIM residents are also trained to assess medically complex patients who often have comorbidities. The goal of this paper was to provide transparency for medical trainees about differences in the proportion of FFS or APP and the average clinical payments made to geriatricians and general internists between the provinces of Canada. Using data from the Canadian Institute for Health Information (CIHI), we show mean, mean trimmed to $100,000 and median clinical payments to geriatricians across Canada. Average payments were generally lower in provinces with predominantly an APP as the main source of payments compared to provinces with a split model of APP and FFS where payments demonstrated larger variances. The clinical payments to general internists were higher than for geriatricians. In addition to increasing transparency in specialist payments, Provincial Medical Associations and Sections or Divisions of Geriatric Medicine, could use these data to advocate for comparable remuneration between geriatricians and general internists when renegotiating clinical payments funding agreements.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e100224
COMPASS‐ND: A unique cohort across the dementia spectrum
Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS‐ND) used wide inclusion criteria recruiting participants across the spectrum from normal cognition to cognitive impairment to all types of clinical dementia, including mixed dementia. 1173 participants comprising 11 diagnostic cohorts, completed screening, clinical, neuropsychology, sensory and motor assessments, magnetic resonance imaging (MRI) and provided biomarker bio‐samples. Method: Recruitment was from advertising and specialty clinics for neurocognitive disorders and/or memory impairment. Robust data monitoring and cleaning occurred on the baseline and Time 2 data. Genetic, MRI, Cerebrospinal Fluid (CSF) and the majority of blood biomarkers analyses have been completed. Result: Data releases uploaded to the Longitudinal Online Research and Imaging System (LORIS) include alpha numeric baseline data, neuroimaging analyses, CSF, genetic and blood biomarkers. 40 autopsies have been completed. 119 data access requests have been submitted to the Data Access Subcommittee. All returning participants will repeat Time 3 extensive clinical and neuropsychology assessments, MRI and provide bio‐samples. Phase III new recruitment will include 400 diverse participants, with up to Grade 12 education, who are not cognitively impaired, or who have cognitive impairment, but not dementia. The balance of each cohort for sex/gender will be a consideration. Conclusion: COMPASS‐ND fills a knowledge gap by recruiting participants representing the full spectrum of neurodegeneration. This distinguishes COMPASS‐ND from other large‐scale studies. Challenges and strategies for engagement and research site level funding will be discussed. Data are available to registered researchers and trainees in Canada and around the world through data access requests.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e100224
Open AccessCOMPASS‐ND: A unique cohort across the dementia spectrum
Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS‐ND) used wide inclusion criteria recruiting participants across the spectrum from normal cognition to cognitive impairment to all types of clinical dementia, including mixed dementia. 1173 participants comprising 11 diagnostic cohorts, completed screening, clinical, neuropsychology, sensory and motor assessments, magnetic resonance imaging (MRI) and provided biomarker bio‐samples. Method: Recruitment was from advertising and specialty clinics for neurocognitive disorders and/or memory impairment. Robust data monitoring and cleaning occurred on the baseline and Time 2 data. Genetic, MRI, Cerebrospinal Fluid (CSF) and the majority of blood biomarkers analyses have been completed. Result: Data releases uploaded to the Longitudinal Online Research and Imaging System (LORIS) include alpha numeric baseline data, neuroimaging analyses, CSF, genetic and blood biomarkers. 40 autopsies have been completed. 119 data access requests have been submitted to the Data Access Subcommittee. All returning participants will repeat Time 3 extensive clinical and neuropsychology assessments, MRI and provide bio‐samples. Phase III new recruitment will include 400 diverse participants, with up to Grade 12 education, who are not cognitively impaired, or who have cognitive impairment, but not dementia. The balance of each cohort for sex/gender will be a consideration. Conclusion: COMPASS‐ND fills a knowledge gap by recruiting participants representing the full spectrum of neurodegeneration. This distinguishes COMPASS‐ND from other large‐scale studies. Challenges and strategies for engagement and research site level funding will be discussed. Data are available to registered researchers and trainees in Canada and around the world through data access requests.
- 8 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4540-4550
History of traumatic brain injury is associated with increased grey-matter loss in patients with mild cognitive impairment
Objectives To investigate whether a history of traumatic brain injury (TBI) is associated with greater long-term grey-matter loss in patients with mild cognitive impairment (MCI). Methods 85 patients with MCI were identified, including 26 with a previous history of traumatic brain injury (MCI[TBI-]) and 59 without (MCI[TBI+]). Cortical thickness was evaluated by segmenting T1-weighted MRI scans acquired longitudinally over a 2-year period. Bayesian multilevel modelling was used to evaluate group differences in baseline cortical thickness and longitudinal change, as well as group differences in neuropsychological measures of executive function. Results At baseline, the MCI[TBI+] group had less grey matter within right entorhinal, left medial orbitofrontal and inferior temporal cortex areas bilaterally. Longitudinally, the MCI[TBI+] group also exhibited greater longitudinal declines in left rostral middle frontal, the left caudal middle frontal and left lateral orbitofrontal areas sover the span of 2 years (median = 1–2%, 90%HDI [−0.01%: −0.001%], probability of direction (PD) = 90–99%). The MCI[TBI+] group also displayed greater longitudinal declines in Trail-Making-Test (TMT)-derived ratio (median: 0.737%, 90%HDI: [0.229%: 1.31%], PD = 98.8%) and differences scores (median: 20.6%, 90%HDI: [−5.17%: 43.2%], PD = 91.7%). Conclusions Our findings support the notion that patients with MCI and a history of TBI are at risk of accelerated neurodegeneration, displaying greatest evidence for cortical atrophy within the left middle frontal and lateral orbitofrontal frontal cortex. Importantly, these results suggest that long-term TBI-mediated atrophy is more pronounced in areas vulnerable to TBI-related mechanical injury, highlighting their potential relevance for diagnostic forms of intervention in TBI.
- 8 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4540-4550
History of traumatic brain injury is associated with increased grey-matter loss in patients with mild cognitive impairment
Objectives To investigate whether a history of traumatic brain injury (TBI) is associated with greater long-term grey-matter loss in patients with mild cognitive impairment (MCI). Methods 85 patients with MCI were identified, including 26 with a previous history of traumatic brain injury (MCI[TBI-]) and 59 without (MCI[TBI+]). Cortical thickness was evaluated by segmenting T1-weighted MRI scans acquired longitudinally over a 2-year period. Bayesian multilevel modelling was used to evaluate group differences in baseline cortical thickness and longitudinal change, as well as group differences in neuropsychological measures of executive function. Results At baseline, the MCI[TBI+] group had less grey matter within right entorhinal, left medial orbitofrontal and inferior temporal cortex areas bilaterally. Longitudinally, the MCI[TBI+] group also exhibited greater longitudinal declines in left rostral middle frontal, the left caudal middle frontal and left lateral orbitofrontal areas sover the span of 2 years (median = 1–2%, 90%HDI [−0.01%: −0.001%], probability of direction (PD) = 90–99%). The MCI[TBI+] group also displayed greater longitudinal declines in Trail-Making-Test (TMT)-derived ratio (median: 0.737%, 90%HDI: [0.229%: 1.31%], PD = 98.8%) and differences scores (median: 20.6%, 90%HDI: [−5.17%: 43.2%], PD = 91.7%). Conclusions Our findings support the notion that patients with MCI and a history of TBI are at risk of accelerated neurodegeneration, displaying greatest evidence for cortical atrophy within the left middle frontal and lateral orbitofrontal frontal cortex. Importantly, these results suggest that long-term TBI-mediated atrophy is more pronounced in areas vulnerable to TBI-related mechanical injury, highlighting their potential relevance for diagnostic forms of intervention in TBI.
- Open Access
- 13 July 2021
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 24 (3) , 200-208
Updated Inventory and Projected Requirements for Specialist Physicians in Geriatrics
Background The predicted growth of Canadians aged 65+ and the resultant rise in the demand for specialized geriatric services (SGS) requires physician resource planning. We updated the 2011 Canadian Geriatrics Society physician resource inventory and created projections for 2025 and 2030. Methods The number and full-time equivalents (FTEs) of geriatricians and Care of the Elderly (COE) physicians working in SGS were determined. FTE counts for 2025 and 2030 were estimated by accounting for retirements and trainees. A ratio of 1.25/10,000 population 65+ was used to predict physician resource requirements. Results Between 2011 and 2019 the number of geriatricians and COE physicians increased from 276 (235.8 FTEs) and 128 (89.9 FTEs), respectively, to 376 (319.6 FTEs) and 354 (115.5 FTEs). This increase did not keep pace with the 65+ population growth. The current gap between supply and need is expected to increase. Discussion The physician supply gap is projected to widen in 2025 and 2030. Increased recruitment and interdisciplinary team-based care, supported by enhanced funding models, and full integration of COE physicians in SGS could reduce this increasing gap. In contrast to pediatrician supply in Canada, the specialist physician resources available to the population 65+ reflect a disparity.
- 13 July 2021
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 24 (3) , 200-208
Open AccessUpdated Inventory and Projected Requirements for Specialist Physicians in Geriatrics
Background The predicted growth of Canadians aged 65+ and the resultant rise in the demand for specialized geriatric services (SGS) requires physician resource planning. We updated the 2011 Canadian Geriatrics Society physician resource inventory and created projections for 2025 and 2030. Methods The number and full-time equivalents (FTEs) of geriatricians and Care of the Elderly (COE) physicians working in SGS were determined. FTE counts for 2025 and 2030 were estimated by accounting for retirements and trainees. A ratio of 1.25/10,000 population 65+ was used to predict physician resource requirements. Results Between 2011 and 2019 the number of geriatricians and COE physicians increased from 276 (235.8 FTEs) and 128 (89.9 FTEs), respectively, to 376 (319.6 FTEs) and 354 (115.5 FTEs). This increase did not keep pace with the 65+ population growth. The current gap between supply and need is expected to increase. Discussion The physician supply gap is projected to widen in 2025 and 2030. Increased recruitment and interdisciplinary team-based care, supported by enhanced funding models, and full integration of COE physicians in SGS could reduce this increasing gap. In contrast to pediatrician supply in Canada, the specialist physician resources available to the population 65+ reflect a disparity.
- 1 December 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 142, 111102
Dual-task gait speed assessments with an electronic walkway and a stopwatch in older adults. A reliability study
- 1 December 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 142, 111102
Dual-task gait speed assessments with an electronic walkway and a stopwatch in older adults. A reliability study
- Open Access
- 1 September 2020
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 23 (3) , 245-253
Ontario Geriatric Specialist Physician Resources 2018
Background The number of older adults with complex health needs in Ontario is growing. The Ministry of Health and Long-Term Care requested a resource mapping project to assess the current 2018 and projected 2025 number of specialist physician resources. Methods Geriatric specialist physicians were defined as geriatricians, geriatric psychiatrists, and Care of the Elderly (COE) physicians. We determined the current number of geriatricians, geriatric psychiatrists, and COEs and clinical full-time-equivalent complement (CFTE) for geriatric medicine and geriatric psychiatry specialists. We projected the number of new trainees expected to enter practice and the number of physicians expected to retire by 2025. We compared these numbers and projections against established specialist/population ratios for geriatricians and geriatric psychiatrists. Results There was a deficit of geriatricians and geriatric psychiatrists (geriatricians: CFTE deficit of 150.5; geriatric psychiatrists: CFTE deficit of 116.3). In 2025, the projected CFTE deficit of geriatricians will increase to at least 210.35 and geriatric psychiatrists to 194.6. Only about 30% of COE physicians work in direct support of specialized services for the elderly. Conclusions There is significant current and anticipated undersupply in the required number of geriatricians, geriatric psychiatrists, and COE physicians to meet anticipated population demand.
- 1 September 2020
- Published by Canadian Geriatrics Society in Canadian Geriatrics Journal
- Vol. 23 (3) , 245-253
Open AccessOntario Geriatric Specialist Physician Resources 2018
Background The number of older adults with complex health needs in Ontario is growing. The Ministry of Health and Long-Term Care requested a resource mapping project to assess the current 2018 and projected 2025 number of specialist physician resources. Methods Geriatric specialist physicians were defined as geriatricians, geriatric psychiatrists, and Care of the Elderly (COE) physicians. We determined the current number of geriatricians, geriatric psychiatrists, and COEs and clinical full-time-equivalent complement (CFTE) for geriatric medicine and geriatric psychiatry specialists. We projected the number of new trainees expected to enter practice and the number of physicians expected to retire by 2025. We compared these numbers and projections against established specialist/population ratios for geriatricians and geriatric psychiatrists. Results There was a deficit of geriatricians and geriatric psychiatrists (geriatricians: CFTE deficit of 150.5; geriatric psychiatrists: CFTE deficit of 116.3). In 2025, the projected CFTE deficit of geriatricians will increase to at least 210.35 and geriatric psychiatrists to 194.6. Only about 30% of COE physicians work in direct support of specialized services for the elderly. Conclusions There is significant current and anticipated undersupply in the required number of geriatricians, geriatric psychiatrists, and COE physicians to meet anticipated population demand.
- Open Access
- 18 June 2020
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 49 (6) , 995-1002
Dual decline in gait speed and cognition is associated with future dementia: evidence for a phenotype
Concurrent declines in gait speed and cognition have been associated with future dementia. However, the clinical profile of ‘dual decliners’, those with concomitant decline in both gait speed and cognition, has not been yet described. We aimed to describe the phenotype and the risk for incident dementia of those who present with dual decline in comparison with non-dual decliners. prospective cohort of community-dwelling older adults free of dementia at baseline. We evaluated participants’ gait speed, cognition, medical status, functionality, incidence of adverse events and dementia, biannually over 7 years. Gait speed was assessed with a 6-m electronic walkway and global cognition using the MoCA test. We compared characteristics between dual decliners and non-dual decliners using t-test, chi-square and hierarchical regression models. We estimated incident dementia using Cox models. among 144 participants (mean age 74.23 ± 6.72 years, 54% women), 17% progressed to dementia. Dual decliners had a 3-fold risk (HR: 3.12, 95%CI: 1.23–7.93, P = 0.017) of progression to dementia compared with non-dual decliners. Dual decliners were significantly older with a higher prevalence of hypertension and dyslipidemia (P = 0.002). Hierarchical regression models show that age and sex alone explained 3% of the variation in the dual decliners group. Adding hypertension and dyslipidemia increased the explained variation by 8 and 10%, respectively. The risk of becoming a dual decliner was 4-fold higher if hypertension was present. older adults with a concurrent decline in gait speed and cognition represent a group at the highest risk of progression to dementia. Older adults with dual decline have a distinct phenotype with a higher prevalence of hypertension, a treatable condition.
- 18 June 2020
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 49 (6) , 995-1002
Open AccessDual decline in gait speed and cognition is associated with future dementia: evidence for a phenotype
Concurrent declines in gait speed and cognition have been associated with future dementia. However, the clinical profile of ‘dual decliners’, those with concomitant decline in both gait speed and cognition, has not been yet described. We aimed to describe the phenotype and the risk for incident dementia of those who present with dual decline in comparison with non-dual decliners. prospective cohort of community-dwelling older adults free of dementia at baseline. We evaluated participants’ gait speed, cognition, medical status, functionality, incidence of adverse events and dementia, biannually over 7 years. Gait speed was assessed with a 6-m electronic walkway and global cognition using the MoCA test. We compared characteristics between dual decliners and non-dual decliners using t-test, chi-square and hierarchical regression models. We estimated incident dementia using Cox models. among 144 participants (mean age 74.23 ± 6.72 years, 54% women), 17% progressed to dementia. Dual decliners had a 3-fold risk (HR: 3.12, 95%CI: 1.23–7.93, P = 0.017) of progression to dementia compared with non-dual decliners. Dual decliners were significantly older with a higher prevalence of hypertension and dyslipidemia (P = 0.002). Hierarchical regression models show that age and sex alone explained 3% of the variation in the dual decliners group. Adding hypertension and dyslipidemia increased the explained variation by 8 and 10%, respectively. The risk of becoming a dual decliner was 4-fold higher if hypertension was present. older adults with a concurrent decline in gait speed and cognition represent a group at the highest risk of progression to dementia. Older adults with dual decline have a distinct phenotype with a higher prevalence of hypertension, a treatable condition.
- Open Access
- 9 February 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-10
Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
Currently there are no disease-modifying treatments for Parkinson’s disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1). Studies in cell culture and animal models have shown that raising the levels of GCase can decrease levels of α-synuclein. Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD. The aims of this trial are to determine if Ambroxol is safe and well-tolerated by individuals with PDD and if Ambroxol affects cognitive, biochemical, and neuroimaging measures. This is a phase II, single-centre, double-blind, randomized placebo-controlled trial involving 75 individuals with mild to moderate PDD. Participants will be randomized into Ambroxol high-dose (1050 mg/day), low-dose (525 mg/day), or placebo treatment arms. Assessments will be undertaken at baseline, 6-months, and 12-months follow up times. Primary outcome measures will be the Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-Cog) and the ADCS Clinician’s Global Impression of Change (CGIC). Secondary measures will include the Parkinson’s disease Cognitive Rating Scale, Clinical Dementia Rating, Trail Making Test, Stroop Test, Unified Parkinson’s disease Rating Scale, Purdue Pegboard, Timed Up and Go, and gait kinematics. Markers of neurodegeneration will include MRI and CSF measures. Pharmacokinetics and pharmacodynamics of Ambroxol will be examined through plasma levels during dose titration phase and evaluation of GCase activity in lymphocytes. If found effective and safe, Ambroxol will be one of the first disease-modifying treatments for PDD. ClinicalTrials.gov NCT02914366, 26 Sep 2016/retrospectively registered.
- 9 February 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-10
Open AccessAmbroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
Currently there are no disease-modifying treatments for Parkinson’s disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1). Studies in cell culture and animal models have shown that raising the levels of GCase can decrease levels of α-synuclein. Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD. The aims of this trial are to determine if Ambroxol is safe and well-tolerated by individuals with PDD and if Ambroxol affects cognitive, biochemical, and neuroimaging measures. This is a phase II, single-centre, double-blind, randomized placebo-controlled trial involving 75 individuals with mild to moderate PDD. Participants will be randomized into Ambroxol high-dose (1050 mg/day), low-dose (525 mg/day), or placebo treatment arms. Assessments will be undertaken at baseline, 6-months, and 12-months follow up times. Primary outcome measures will be the Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-Cog) and the ADCS Clinician’s Global Impression of Change (CGIC). Secondary measures will include the Parkinson’s disease Cognitive Rating Scale, Clinical Dementia Rating, Trail Making Test, Stroop Test, Unified Parkinson’s disease Rating Scale, Purdue Pegboard, Timed Up and Go, and gait kinematics. Markers of neurodegeneration will include MRI and CSF measures. Pharmacokinetics and pharmacodynamics of Ambroxol will be examined through plasma levels during dose titration phase and evaluation of GCase activity in lymphocytes. If found effective and safe, Ambroxol will be one of the first disease-modifying treatments for PDD. ClinicalTrials.gov NCT02914366, 26 Sep 2016/retrospectively registered.
- Open Access
- 1 January 2019
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 5 (1) , 501-507
The case‐finding study: A novel community‐based research recruitment approach for engaging participants with early cognitive decline
Introduction: Innovative recruitment strategies are needed to better engage potential research participants at a preclinical stage of cognitive decline. Methods: Local newspaper advertisements attracted community‐dwelling people ≥55 years with memory concerns, who were interested in research, to self‐refer for cognitive assessment and discuss cognitive research involvement. Respondents completed telephone screening and then attended an in‐person cognitive screening assessment with a study partner. Case conferencing with a clinician researcher characterized a “clinical suspicion” of the participant's cognitive concern. Results: Of 209 respondents who underwent in‐person assessment, 203 participants were classified as having subjective cognitive decline (47%), mild cognitive impairment (44%), or dementia (9%). Thirty percent of participants were enrolled in observational studies or randomized controlled trials. Discussion: Community‐based engagement, cognitive screening, and case conferencing effectively combined to identify research participants at risk of cognitive decline and recruited participants into cognitive research studies. Those not recruited continued to be followed up longitudinally.
- 1 January 2019
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 5 (1) , 501-507
Open AccessThe case‐finding study: A novel community‐based research recruitment approach for engaging participants with early cognitive decline
Introduction: Innovative recruitment strategies are needed to better engage potential research participants at a preclinical stage of cognitive decline. Methods: Local newspaper advertisements attracted community‐dwelling people ≥55 years with memory concerns, who were interested in research, to self‐refer for cognitive assessment and discuss cognitive research involvement. Respondents completed telephone screening and then attended an in‐person cognitive screening assessment with a study partner. Case conferencing with a clinician researcher characterized a “clinical suspicion” of the participant's cognitive concern. Results: Of 209 respondents who underwent in‐person assessment, 203 participants were classified as having subjective cognitive decline (47%), mild cognitive impairment (44%), or dementia (9%). Thirty percent of participants were enrolled in observational studies or randomized controlled trials. Discussion: Community‐based engagement, cognitive screening, and case conferencing effectively combined to identify research participants at risk of cognitive decline and recruited participants into cognitive research studies. Those not recruited continued to be followed up longitudinally.
- Open Access
- 7 December 2018
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 10 (1) , 120
Correction to: The Toronto cognitive assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment
Upon publication of this article [1], it was brought to our attention that one of the 303 participants in the normative study should have been deleted from the database.
- 7 December 2018
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 10 (1) , 120
Open AccessCorrection to: The Toronto cognitive assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment
Upon publication of this article [1], it was brought to our attention that one of the 303 participants in the normative study should have been deleted from the database.